bioecon Member area
Technology · Synbio & enabling tech / Foundries & design

Cell-free systems & cell-free bioproduction

Cell-free protein synthesis (CFPS) bypasses the living cell: ribosomes and translation factors in a reaction tube deliver the target protein in hours, not weeks, with toxic and non-canonical amino acids incorporated.

Maturity 5/9 Risk: medium Research tools & R&D services US · CN · EU Science: why it works →Forums and policy: 4 verified 2026-06-19 · 0 Sources (0 independent)

1 · What it gives

Cell-free systems (Cell-Free Protein Synthesis, CFPS) are a paradigm that dispenses with the living host cell in industrial synthesis: only the molecular translation machines (ribosomes, tRNAs, initiation/elongation/termination factors) are extracted from organisms and assembled in a reaction tube with a DNA template, amino acids and an ATP-regeneration system. A living cell spends up to 80% of its resources on its own metabolism; a cell-free system directs all activity to the product, cutting synthesis from weeks to hours and enabling proteins toxic to cells as well as non-canonical amino-acid incorporation.

Key platforms of cell-free production:

  1. Cell-lysate CFPS (Cell Lysate CFPS): E. coli, CHO, wheat-germ extracts — a ready translation complex.
  2. Reconstituted PURE (PURE): 36 purified E. coli enzymes, no endogenous proteases — absolute purity.
  3. Enzymatic cascades (Cell-Free Cascades): 10–20 thermostable enzymes turn sugars into chemicals without a cell.
  4. Paper sensors (Paper TX-TL): lyophilised TX-TL + riboswitches for field diagnostics.

Sectoral value chain#

[producer culture] ──> [lysis & centrifugation] ──> [lysate]
                                                       │
                                              (DNA + ATP cascade)
                                                       │
                                                       ▼
[target protein] <─── [affinity purification] <─── [in-vitro synthesis, hours]

Value chain levels#

LevelDescriptionKey inputs/outputs
Lysate Productioncell cultivation, lysis, ribosome/enzyme isolationIn: cells, homogenisers. Out: standardised lysate.
Energy FormulationATP-regeneration buffer (phosphoenolpyruvate/glucose)In: cofactors, amino acids. Out: energy mix.
DNA Templatede novo synthesis/amplification with a T7 promoterIn: digital gene design. Out: DNA template.
In-Vitro Synthesismixing lysate, buffer, template at +30–37°CIn: lysate, buffer, template. Out: reaction mix.
Purificationaffinity chromatography and filtrationIn: reaction mix. Out: pure protein.
On-Demand Distributionlyophilised kits for on-the-spot synthesisIn: lyophilate, cartridges. Out: on-site kits.

Cross-cutting technologies of the sector:

  • Cheap-substrate ATP regeneration: 10–12-enzyme cascades on glucose/starch cut energy cost 100×.
  • Non-canonical amino acids (nSAA): re-assigning tRNA/synthetases to incorporate artificial amino acids (ADC, click chemistry).
  • Continuous-flow microfluidic reactors: continuous substrate feed and inhibitor removal — day-long synthesis.

2 · What it replaces 0 · matched by industry

No graded substitution linked yet.

3 · How to implement 6 steps

  1. 1
    CHO lysate
    CHO are grown in a cGMP reactor, detergent lysis, 30,000 g centrifugation, own-mRNA removal with micrococcal nuclease.
  2. 2
    Reaction mix
    The reactor is loaded with lysate, antibody DNA template, energy buffer, amino acids and the non-canonical amino acid (pAMF) at the UAG codon.
  3. 3
    Cell-free synthesisSynthesis & conversion
    At +32°C, continuous substrate feed and inhibitor dialysis; T7 translation yields the modified antibody in 10 h at 2.5 g/L.
    Who can do this step matched automatically
    1,200 tons industrial scale
    “is a biotechnology company specializing in green pharmaceutical technology, biocatalysis, and synthetic biology.”
    industrial scale
    “First-generation biomanufacturing: Fermentation-based production of organic acids, amino acids, vitamins, alcohols, and related bio-based products from starch (corn, cassava) using …”
    75,000 tonnes per year pilot scale
    “Its core technology involves the polymerization of lactic acid into high-performance PLA grades used in packaging, automotive components, 3D printing, and consumer goods.”
  4. 4
    Affinity purificationPurification & downstream
    Protein A Sepharose binds the antibody; elution at pH 3.0, neutralisation to pH 7.2.
    Who can do this step matched automatically
    ✓ ISO 9001
    “Crystallization and refining: In-house developed DP Crystallizer and Oslo Crystallizer for tailored crystallization and refining processes; integrated purification units combining …”
    ✓ ISO 9001 industrial scale
    “Minimal processing that preserves essential nutrients and phytochemicals via their PS 2.0 downstream process, avoiding cell damage and nutrient loss.”
    industrial scale
    “With fungal and bacterial secretion systems, we custom produce the evolved enzyme products in large-scale fermentation and downstream processes.”
    1,200 tons industrial scale
    “CRO/CDMO and Testing/Quality Research Services: Comprehensive contract research and development, analytical, and quality assessment capabilities with access to NMR, LC-MS, GC-MS, …”
    ScaleUp Bio Singapore
    10,000 L pilot scale
    “Core capabilities span pilot-industrial fermentation and downstream unit operations (centrifugation, TFF, chromatography, solvent extraction, spray/freeze drying) with cGMP …”
  5. 5
    Click chemistry
    DBCO-linker-toxin (MMAE) reacts with the antibody azide groups in 2 h; fixed DAR = 2.0.
  6. 6
    Final controlPurification & downstream
    Sterile 0.22 µm filtration, lyophilisation, MALDI-TOF DAR control, sterility and pyrogen testing.
    Who can do this step matched automatically
    ✓ ISO 9001
    “Crystallization and refining: In-house developed DP Crystallizer and Oslo Crystallizer for tailored crystallization and refining processes; integrated purification units combining …”
    ✓ ISO 9001 industrial scale
    “Minimal processing that preserves essential nutrients and phytochemicals via their PS 2.0 downstream process, avoiding cell damage and nutrient loss.”
    industrial scale
    “With fungal and bacterial secretion systems, we custom produce the evolved enzyme products in large-scale fermentation and downstream processes.”
    1,200 tons industrial scale
    “CRO/CDMO and Testing/Quality Research Services: Comprehensive contract research and development, analytical, and quality assessment capabilities with access to NMR, LC-MS, GC-MS, …”
    ScaleUp Bio Singapore
    10,000 L pilot scale
    “Core capabilities span pilot-industrial fermentation and downstream unit operations (centrifugation, TFF, chromatography, solvent extraction, spray/freeze drying) with cGMP …”

4 · Who delivers

Matched suppliers (matched automatically)

Simple PlanetSouth KoreaProduceractive
IntegricultureJapanEquipmentactive
UMAMI BioworksSingaporeProduceractive
CellMEATSouth KoreaProduceractive
Aleph FarmsIsraelProduceractive
ImpacFatSingaporeProduceractive
UnibioDenmarkProduceractive
PenséesSouth KoreaProduceractive

In the services and supply catalogue 1 · paid service

Contract manufacturing (CMO/CDMO/toll)

Leading companies and institutes (from the brief)

Company / InstituteCountryKey products / platformsTech featuresStatus 2026
Sutro Biopharma🇺🇸 USAXpressCF® (CDMO)CHO/E. coli CFPS to thousands of L; toxic proteins, ADCsCommercial
GreenLight Biosciences🇺🇸 USAcell-free RNA platformsenzymatic dsRNA/mRNA synthesis by the tonneCommercial
GeneFrontier🇯🇵 JapanPUREfrex®36 purified enzymes, no proteasesCommercial
TIB CAS🇨🇳 ChinaASAP (starch from CO2)11-enzyme cascade, 8.5× photosynthesisResearch
Swiftscale Biotherapeutics🇺🇸 USArapid CFPSDNA→protein in 24 h (personalised oncology)Scaling
Northwestern University🇺🇸 USAon-demand TX-TL kitspaper/cartridge lyophilisation (Jewett Lab)Research

5 · Rules & route to market

United States

The US leads CFPS commercialisation for therapeutic proteins and RNA pesticides (DARPA, VC).

Sutro, GreenLight, Jewett Lab, DARPA on-demand pharmacy#

  • Sutro Biopharma: XpressCF® platform on E. coli/CHO lysate — antibodies and ADCs, reactors to thousands of litres.
  • GreenLight Biosciences: cell-free dsRNA and mRNA synthesis (agro-pesticides, vaccines) by the tonne.
  • DARPA On-Demand Pharmacy + Jewett Lab (Northwestern): portable synthesis suitcases from lyophilised cartridges.

European Union

The EU leads in high-purity PURE systems and safety standards for cell-free output.

PUREfrex (GeneFrontier), Horizon Europe, Max Planck/CNRS#

  • PUREfrex (GeneFrontier): reconstituted system of 36 enzymes — protein screening free of bacterial LPS.
  • Horizon Europe: microfluidic/membrane reactors for food and textile enzymes.
  • Max Planck/CNRS: artificial cells — cell-free systems in lipid vesicles.

China

China bets on large-scale cell-free enzymatic cascades (CAS, TIB).

TIB CAS, cell-free starch from CO2, cascade biocatalysis#

  • TIB CAS (ASAP): an 11-enzyme cascade synthesises starch from CO2/H2 — 8.5× maize photosynthesis.
  • Multi-step biocatalysis: rare sugars (allulose, tagatose), inositol, amino acids without live GMOs.
  • National key R&D program: immobilised enzymes for continuous industrial reactors.

6 · Money: tenders & grants

7 · Tech stack & innovations

The stack rests on PURE, cheap ATP regeneration and genetic-code expansion.

  1. PURE (reconstituted translation):
    • 36 purified E. coli enzymes + 70S ribosomes; no proteases/nucleases → absolute-purity proteins.
  2. Cheap-substrate ATP cascades:
    • maltodextrin phosphorylase + a starch/glucose cascade — ATP regeneration 100× cheaper.
  3. Genetic-code expansion:
    • RF1-free lysates (C321.∆A) — amber codon for a non-canonical amino acid (p-azidophenylalanine) for ADC click chemistry.

Where this appears 4 sources

Appears in 4 distinct sources across 1 region, 2023–2025.

  • policy documents 1
  • reports 3

Regions: China

Distinct sources per year
  1. 2021: 0
  2. 2022: 0
  3. 2023: 1
  4. 2024: 1
  5. 2025: 2
  6. 2026: 0
  7. 2027: 0

Matched themes 2

Cell-free systems 无细胞合成生物学

Themes from forum programmes, policy documents and reports are mapped to technologies automatically and then reviewed; counts are distinct sources, not mentions, and are not a ranking. data sources and method → · Trending, not yet covered →

Sources 0 · 0 independent · 0 producer sites